The long-term outlook for the Eylea market is heavily reliant on successfully transitioning patients to the high-dose Eylea HD and staving off the full impact of biosimilar market entry, making accurate Eylea Market forecast a high-stakes endeavor for investors and manufacturers alike. Initial forecasts project a period of revenue moderation, or even a slight decline for the legacy Eylea 2 mg brand, which will be directly attributable to the imminent launch of aflibercept biosimilars in the United States and other major economies. However, this contraction is expected to be substantially mitigated—and possibly reversed—by the rapid adoption of Eylea HD, whose extended dosing interval presents a superior convenience and clinical profile compared to the standard dose and likely to the first-generation biosimilars. This premium product introduction effectively acts as a strategic product lifecycle extension, allowing the brand to maintain a significant revenue stream and protect a substantial portion of its market share. The core assumption underlying positive long-term projections is the clinical non-inferiority and superior patient adherence achieved with the longer treatment intervals of Eylea HD, which translates directly into better visual outcomes for patients and a more manageable treatment schedule for healthcare providers. Furthermore, the global market for anti-VEGF therapies continues to expand structurally due to the increasing diagnosis and treatment of retinal diseases, particularly in emerging economies where access to advanced care is improving. Therefore, while pricing pressure is inevitable, the sheer volume of new patients entering the treatment paradigm for wAMD, DME, and retinal vein occlusion (RVO) will ensure sustained growth for the overall therapeutic class. Future market size will also be influenced by regulatory decisions concerning new indications and the acceptance of Eylea HD's longest possible dosing intervals, which will be crucial for maximizing its competitive advantage against both branded rivals and biosimilars.

The trajectory of the Eylea market beyond the immediate patent expiration period will be characterized by a shift in competitive focus from raw efficacy—which is relatively mature across the anti-VEGF class—to dosing regimen flexibility and novel delivery mechanisms. The Eylea Market forecast must, therefore, incorporate the potential impact of truly long-acting therapies, such as gene therapies currently in development, which promise a one-time or very infrequent treatment approach for chronic retinal diseases. While these are not yet commercial, their progress in the clinical pipeline represents the next major competitive wave that all existing anti-VEGF therapies must contend with. Regeneron and Bayer are proactively participating in this evolutionary race by exploring sustained-release technologies and combination therapies to ensure Eylea remains relevant in an environment where patient burden minimization is the ultimate value differentiator. The market's regional growth patterns are also a critical factor; while North America and Europe remain the largest revenue contributors, the Asia-Pacific region is poised for the fastest expansion, driven by rising diabetes prevalence and improving healthcare infrastructure. Strategic pricing and market access initiatives in these high-growth areas will be essential to capture new patient populations and counterbalance the pricing erosion in established markets. Overall, the market is forecasted to stabilize and continue its moderate growth, pivoting on the successful commercial execution of Eylea HD and the ability to demonstrate superior real-world value over biosimilar entrants. For a comprehensive look at the market, see this Eylea Market forecast.